Autologous Platelet-Rich Plasma for Reducing Intraoperative Blood Loss in Neurosurgery: A Randomized Controlled Trial versus Standard Hemostatic Measures

INTERVENTION: Intervention1: application of PRP‐PL as homeostatic agent in stereotactic biopsy.: in one group no agent will be applied, in 2nd group TGM and in 3rd group PRP‐PL will be used after biopsy procedure. Control Intervention1: use of PRP‐PL and TGM in group 2 & 3 and while in group 1, conventional method of post biopsy will be performed.: use of PRP‐PL and TGM in group 2 & 3 and while in group 1, conventional method of post biopsy will be performed. CONDITION: Health Condition 1: C719‐ Malignant neoplasm of brain, unspecified PRIMARY OUTCOME: ncidence of post‐biopsy (1 ‐4 hours) hemorrhage (Seen on post‐biopsy CT scan).Timepoint: ncidence of post‐biopsy (1 ‐4 hours) hemorrhage (Seen on post‐biopsy CT scan). SECONDARY OUTCOME: development of new hemoastaic agent for Neurosurgical cases.Timepoint: 4‐12 hours INCLUSION CRITERIA: 1. Patients who are undergoing stereotactic biopsy for suspected primary or secondary brain tumors. 2. Patients age between 18‐75years. 3. Patients who have no known bleeding disorders or no coagulation proflle abnormality. 4. Pateints/Patients party give consent for participation in the study.